Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial.
Karver TS, Pascual-Bernaldez M, Berni A, Hnoosh A, Castagna A, Messiaen P, Puerto MJG, Bloch M, Adachi E, Sinclair G, Felizarta F, Angel JB, Sutton K, Sutherland-Phillips D, D'Amico R, Kerrigan D. Karver TS, et al. Among authors: adachi e. AIDS Patient Care STDS. 2023 Jan;37(1):53-59. doi: 10.1089/apc.2022.0168. AIDS Patient Care STDS. 2023. PMID: 36626155 Clinical Trial.
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann PJ, Pekosz A, Kawaoka Y. Uraki R, et al. Among authors: adachi e. Lancet Infect Dis. 2023 Apr;23(4):402-403. doi: 10.1016/S1473-3099(23)00070-1. Epub 2023 Feb 8. Lancet Infect Dis. 2023. PMID: 36773622 Free PMC article. No abstract available.
Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Furusawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Uraki R, et al. Among authors: adachi e. Lancet Infect Dis. 2023 May;23(5):525-526. doi: 10.1016/S1473-3099(23)00132-9. Epub 2023 Mar 7. Lancet Infect Dis. 2023. PMID: 36898405 Free PMC article. No abstract available.
Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Theiler J, Yotsuyanagi H, Suzuki Y, Korber B, Kawaoka Y. Uraki R, et al. Among authors: adachi e. Lancet Reg Health West Pac. 2023 May;34:100777. doi: 10.1016/j.lanwpc.2023.100777. Epub 2023 May 11. Lancet Reg Health West Pac. 2023. PMID: 37193320 Free PMC article. No abstract available.
Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination.
Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, Kamimoto S, Ogura T, Hagiwara S, Kato H, Nakajima H, Uwamino Y, Yagi K, Sugaya N, Nagai H, Saito M, Adachi E, Koga M, Tsutsumi T, Duong C, Okuda M, Murakami J, Furusawa Y, Ujie M, Iwatsuki-Horimoto K, Yotsuyanagi H, Kawaoka Y. Yamamoto S, et al. Among authors: adachi e. iScience. 2023 Jun 25;26(7):107208. doi: 10.1016/j.isci.2023.107208. eCollection 2023 Jul 21. iScience. 2023. PMID: 37448563 Free PMC article.
Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Fukushi S, Watanabe S, Suzuki T, Kikuchi T, Yotsuyanagi H, Maeda K, Kawaoka Y. Uraki R, et al. Among authors: adachi e. iScience. 2023 Oct 4;26(11):108147. doi: 10.1016/j.isci.2023.108147. eCollection 2023 Nov 17. iScience. 2023. PMID: 37876803 Free PMC article.
386 results